Tuesday, Sep 2, 2003
South San Francisco, Calif. -- September 2, 2003 --Genentech, Inc. (NYSE:DNA) invites investors, the media and the general public to listen to a webcast of a discussion following the Food and Drug Administration's Dermatologic and Opththalmic Drugs Advisory Committee (DODAC) review of the Biologics License Application for Raptiva (Efalizumab) for the treatment of moderate-to-severe plaque psoriasis in adults.
The webcast will begin at 3:00pm Pacific Time on September 9, 2003. The live webcast can be accessed by going to Genentech's website at http://www.gene.com and will be archived and available for replay until 5:00pm Pacific Time on September 16, 2003.
An audio replay of the webcast will be available beginning at 5:00pm Pacific Time on September 9, 2003 and ending at 5:00pm Pacific Time on September 16, 2003. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); passcode number is 2287750.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Sixteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 11 biotechnology products in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.